Literature DB >> 20227492

A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling.

Nicolas Szabo-Fresnais1, Florence Lefebvre, Aurore Germain, Rodolphe Fischmeister, Martine Pomérance.   

Abstract

The sympathetic nervous system and pro-inflammatory cytokines play key roles in numerous cardiovascular disorders. Chronic beta-adrenergic receptor (beta-AR) stimulation in myocardium induces expression of pro-inflammatory cytokines, such as interleukin-1 (IL-1) and interleukin-6 (IL-6), which contribute to cardiac hypertrophy and failure. To evaluate the relationship between beta-AR stimulation and pro-inflammatory cytokines, we studied the effects of the beta-AR agonist isoprenaline (ISO) on IL-1-induced IL-6 production in adult rat ventricular myocytes (ARVMs). We report that ISO and IL-1 synergistically enhanced IL-6 gene expression and secretion. The synergistic effect of ISO was mimicked by cAMP elevating agents and involved the G(s) protein/cAMP/PKA signalling pathway, but not the exchange factor EPAC. To evaluate the contribution of IL-6 to cellular hypertrophy, we examined the signalling pathways stimulated by the membrane-bound IL-6 receptor (IL-6R), and the IL-6 soluble receptor (sIL-6R) involved in the mechanism named IL-6 trans-signalling. The IL-6/sIL-6R complex promoted a rapid and persistent phosphorylation of STAT3(Tyr705) in ARVMs. Moreover, IL-6 trans-signalling increased protein synthesis, c-fos gene expression and B-type natriuretic peptide secretion, three markers of cardiac hypertrophy. IL-6 trans-signalling also increased cell size. In contrast, IL-6 alone had no significant effect on either cell size or STAT3 phosphorylation although it induced phosphorylation of ERK1/2, AKT and S6K, demonstrating the presence of a functional IL-6R in ARVMs. Taken together, these results demonstrate that beta-AR stimulation synergises with IL-1 for IL-6 secretion in adult ventricular myocytes and indicate that IL-6 induces cardiac hypertrophy only via IL-6 trans-signalling. The IL-6 soluble receptor may thus serve as a switch for IL-6 to activate STAT3 phosphorylation and hypertrophy. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227492     DOI: 10.1016/j.cellsig.2010.03.009

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  24 in total

1.  Crosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: a recipe for impaired wound healing.

Authors:  Mohan R Dasu; Sandra R Ramirez; Thi Dinh La; Farzam Gorouhi; Chuong Nguyen; Benjamin R Lin; Chelcy Mashburn; Heather Stewart; Thomas R Peavy; Jan A Nolta; Roslyn R Isseroff
Journal:  Stem Cells Transl Med       Date:  2014-04-23       Impact factor: 6.940

2.  Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway.

Authors:  Xiuli Fang; Yajun Liu; Jing Lu; Huiqi Hong; Jing Yuan; Yuhong Zhang; Panxia Wang; Peiqing Liu; Jiantao Ye
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-21       Impact factor: 3.000

3.  Interleukin 33 as a mechanically responsive cytokine secreted by living cells.

Authors:  Rahul Kakkar; Hillary Hei; Stephan Dobner; Richard T Lee
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

Review 4.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

5.  Inflammation and Circulating Natriuretic Peptide Levels.

Authors:  Hannah Fish-Trotter; Jane F Ferguson; Nirav Patel; Pankaj Arora; Norrina B Allen; Katherine N Bachmann; Lori B Daniels; Muredach P Reilly; Joao A C Lima; Thomas J Wang; Deepak K Gupta
Journal:  Circ Heart Fail       Date:  2020-06-08       Impact factor: 8.790

6.  Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias.

Authors:  Toshitaka Yajima; Yoshiteru Murofushi; Hanbing Zhou; Stanley Park; Jonathan Housman; Zhao-Hua Zhong; Michinari Nakamura; Mitsuyo Machida; Kyung-Kuk Hwang; Yusu Gu; Nancy D Dalton; Tomoko Yajima; Hideo Yasukawa; Kirk L Peterson; Kirk U Knowlton
Journal:  Circulation       Date:  2011-11-14       Impact factor: 29.690

7.  IL-6 signalling in patients with acute ST-elevation myocardial infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Thomas Weiss; Jan Eritsland; Geir Ø Andersen
Journal:  Results Immunol       Date:  2013-12-14

Review 8.  The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response.

Authors:  Michael A Wagner; M A Q Siddiqui
Journal:  JAKSTAT       Date:  2012-04-01

Review 9.  Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure.

Authors:  Liza Grosman-Rimon; Filio Billia; Evan Wright; Shemy Carasso; Gabby Elbaz-Greener; Erez Kachel; Vivek Rao; David Cherney
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

10.  p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation.

Authors:  Ahmed Fahmi; Nicola Smart; Anu Punn; Rita Jabr; Michael Marber; Richard Heads
Journal:  Cell Signal       Date:  2012-12-23       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.